


DAPT

ALTERNATE NAME: N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine *t*-Butyl Ester

CATALOG #: 1855-5

AMOUNT: 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₃H₂₆F₂N₂O₄

MOLECULAR WEIGHT: 432.46

CAS NUMBER: 208255-80-5

APPEARANCE: White to off-white solid

SOLUBILITY: DMSO (~20 mg/ml)

PURITY: ≥98% by TLC

STORAGE: Store at -20 °C

DESCRIPTION: Cell permeable. A potent inhibitor of γ -secretase (IC₅₀ = 115 nM for total β -amyloid, IC₅₀ = 200 nM for β -amyloid 1-42). It reduces A β levels *in vivo* in plasma and cerebrospinal fluid in young and aged Tg2576 mice. Antagonizes Notch signaling through inhibition of Notch processing. DAPT treatment can influence hematopoietic cell fate decisions and enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independent of sonic hedgehog (shh) signaling.

REFERENCE: Crawford, T.Q. and Roelink, H. (2007). *Dev. Dyn.* **236**, 886-892.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

FOR RESEARCH USE ONLY! Not to be used on humans.

RELATED PRODUCTS

- Compound 1 (Cat. No. 1688-1)
- Cyclopamine (Cat. No. 1578-5)
- Cyclosporine A (Cat. No. 1522-100, 1G)
- Dexamethasone (Cat. No. 1042-1G, 10G)
- Forskolin, *Coleus Forskohlii* (Cat. No. 1531-5)
- Geldanamycin (Cat. No. 1564-1,5)
- Hh Signaling Pathway Antagonist (Cat. No. 1659-1)
- JK 184 (Cat. No. 1726-1)
- Purmorphamine (Cat. No. 1672-5)
- Rapamycin (Cat. No. 1568-5,50)
- EZSolution™ Rapamycin (Cat. No. 1746-5)
- Reversine (Cat. No. 1851-1, 5)
- SB-431542 (Cat. No. 1674-1)
- Sodium Butyrate (Cat. No. 1609-1000)
- Stauprimide (Cat. No. 1743-500)
- Trichostatin A (Cat. No. 1606-1)
- U0126 (Cat. No. 1668-5)